

Zealand Pharma A/S convenes an Extraordinary General Meeting

Notice to convene an Extraordinary General Meeting of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company").

The Board of Directors of the Company hereby convenes an Extraordinary General Meeting (the "General Meeting") of the Company to be held on:

Tuesday, May 26, 2026, at 1:00 pm (CEST)

The General Meeting will be held as a physical meeting at Plesner Advokatpartnerselskab, Amerika Plads 37, 2100 Copenhagen Ø, Denmark.

No live webcast or recording will be made in connection with the General Meeting.

Please refer to pages 2-5 for further information.

Agenda:

- (1) Election of new member to the Board of Directors
- (2) Authorization to the chair of the general meeting

Complete proposals:

Re item (1):

The Board of Directors proposes that Camilla Sylvest be elected as a member of the Board of Directors, in accordance with the recommendation of the Company's Nomination Committee, until the next Annual General Meeting of the Company.

For a description of Camilla Sylvest's competencies and current positions, see [Appendix 1](#) to this notice.

No other changes to the composition of the Company's shareholder-elected members of the Board of Directors are proposed. Accordingly, the Board of Directors is expected to consist of the shareholder-elected board members Martin Nicklasson, Kirsten Aarup Drejer, Leonard Kruimer, Elaine Sullivan, Enrique Conterno, Iris Löw-Friedrich and Camilla Sylvest, all elected for a term until the next Annual General Meeting, together with the employee-elected board members Anneline Nansen, Nikolaj Frederik Beck, Adam Krisko Nygaard, and Ludovic Tranholm Otterbein, who have been elected for a term until 2028.

Re item (2):

The Board of Directors proposes that the chair of the general meeting be authorized to make such alterations, amendments or additions to the resolutions passed by the General Meeting and the application for registration of the resolutions to be filed with the Danish Business Authority (Erhvervsstyrelsen) as the authority may require for registration.

- 0 -

Language

The General Meeting is held in English without any translation into Danish in accordance with Article 9.11 of the Company's Articles of Association.



Resolution requirements

The following requirements are applicable in order to pass the resolutions and must be fulfilled in order for the proposals to be adopted:

The proposals set out in items (1) and (2) of the agenda must be adopted by a simple majority of votes.

- 0 -

General share information

The share capital of the Company is nominally DKK 71,525,575. The nominal amount of each share is DKK 1. Each share of nominally DKK 1 carries one vote at the General Meeting.

The shareholders may exercise their financial rights through their own depository banks.

Information on the Company's website

Further information about the General Meeting will be available from the date of this notice on the Company's website: <https://www.zealandpharma.com/investors/extraordinary-general-meeting-may-2026>:

- 1) The total number of shares and voting rights in the Company on the date of the notice
- 2) This notice to convene, along with the agenda and the complete proposals
- 3) A proxy / postal vote form
- 4) The documents to be presented at the General Meeting, including a description of the nominated candidate (Appendix 1).

Publication of notice

This notice has been made public via the electronic IT system of the Danish Business Authority, on the Company's website: <https://www.zealandpharma.com/investors/extraordinary-general-meeting-may-2026> and further, information about the General Meeting will be transmitted via the Company's depository bank (Danske Bank A/S) through the chain of intermediaries (GOR). This notice has also been sent electronically to all shareholders who have registered their e-mail address with the Company and by ordinary mail to shareholders having requested so.

Request for notice to convene by ordinary mail

Please note that shareholders need to notify the Company each year, via the Company's shareholder portal, if they wish to receive the notice to convene for the General Meeting by ordinary mail instead of e-mail.

Questions

Shareholders may submit questions in writing concerning the agenda and the other material relating to the General Meeting.

Questions submitted in advance of the General Meeting must be received by the Company no later than Friday, 22 May 2026 at 11:59 pm (CEST). Questions can be submitted by e-mail to egm2026@zealandpharma.com or by ordinary mail and will be answered in writing or orally at the General Meeting, unless the answer is made available on the Company's website: <https://www.zealandpharma.com/investors/extraordinary-general-meeting-may-2026>.

Shareholders attending the General Meeting in person will also be able to ask questions at the General Meeting. Questions received during the General Meeting will be answered orally at the General Meeting.

- 0 -



In order to attend the General Meeting and vote, the following apply:

Date of registration

The shareholders' right to attend and vote at the General Meeting, or to vote by post, is determined based on the shares that the shareholders hold on the date of registration (in Danish: *registreringsdato*), which is Tuesday, May 19, 2026.

Only persons who are shareholders of the Company at the expiry of the registration date may attend and vote at the General Meeting.

Once the date of registration has passed, the number of shares held by each shareholder will be determined. This determination is based on the registration of shares in the Company's register of shareholders, as well as on notifications of ownership received by the Company before the date of registration for the purpose of registration in the register of shareholders, but which have not yet been entered in the register of shareholders.

The calculation for a specific shareholder requires that the shareholder's shares are registered in the shareholder's own name (in Danish: *navnenotering*) in a separate or segregated share account. Accordingly, the Company's shares are generally issued in the name of the holder and must be registered as such in the Company's register of shareholders. A request for registration of shares in the shareholder's own name (in Danish: *navnenotering*) must be submitted through the shareholder's own custodian bank, nominee, or financial adviser, as applicable, if the shareholder is not already registered by name in the Company's register of shareholders.

Shareholders who hold shares in the Company through a nominee are therefore not registered in their own name and must exercise their voting rights through the nominee structure. This means that any votes, including amendments to votes submitted by proxy, must be submitted to the Company by the nominee on the shareholder's behalf. Shareholders holding shares through nominees or nominee accounts are therefore encouraged to contact their bank or financial service provider for advice on the applicable procedures.

Admission card

In order to attend the General Meeting, shareholders must order an admission card no later than Friday, 22 May 2026 at 11:59 pm (CEST).

Admission cards may be requested as follows:

- Electronically via the Company's shareholder portal available at <https://portal.computershare.dk/portal/index.asp?asident=21196>
- By contacting Computershare A/S; by telephone +45 45460997, by e-mail to gf@computershare.dk or by written enquiry to Computershare A/S, Lottenborgvej 26D, 1st floor, DK-2800 Kgs. Lyngby, Denmark.

Upon registration, a confirmation with the admission details enclosed will be sent out electronically via email to the email address specified in the Company's shareholder portal. If no email address is specified in the Company's shareholder portal, shareholders may download and/or print the admission details through the shareholder portal accessed via <https://portal.computershare.dk/portal/index.asp?asident=21196>.

A shareholder (or the shareholder's duly appointed proxy holder) may attend the General Meeting together with an advisor, provided that the shareholder or any proxy holder, as applicable, has duly requested admission for the advisor's participation.

If the admission details are lost or in case of any issues with accessing the General Meeting, Computershare A/S will provide technical assistance. Computershare A/S will be available Tuesday, May 26, 2026 from 12:15 pm (CEST) and during the General Meeting.



Attending the General Meeting

Attending the General Meeting requires the timely ordering of an admission card as further indicated above.

Shareholders attending the General Meeting shall present the admission card at the entrance of the General Meeting either electronically on a smartphone/tablet or in a printed version.

Any voting will take place electronically via the virtual EGM portal and further information will follow at the General Meeting (if relevant).

The doors to the General Meeting will open at 12:15 pm (CEST).

Proxy

A shareholder may attend and vote at the General Meeting by proxy. Proxy appointments must be made by submitting a completed and signed proxy form to Computershare A/S no later than Friday, 22 May 2026 at 11:59 pm (CEST).

Generally, proxy arrangements include the following options:

- Appoint a proxy to a named third party. If you attend the General Meeting by proxy, your designated proxy holder will receive admission documentation from Computershare A/S, which must be presented at the entrance to the General Meeting.
- Appoint a proxy to the Board of Directors. In this case, your votes will be cast in accordance with the Board of Directors' recommendations.
- Appoint a proxy to the Board of Directors with specific voting instructions. In this case, the Board of Directors will vote in accordance with your instructions.

Shareholders who hold shares in the Company through a nominee must exercise their voting rights through the nominee structure. This means that any votes, including amendments to votes submitted by proxy, must be submitted to the Company by the nominee on the shareholder's behalf. Shareholders holding shares through nominees or nominee accounts are therefore encouraged to contact their bank or financial service provider for advice on the applicable procedures.

It is possible to submit a proxy form electronically directly via the Company's shareholder portal available at <https://portal.computershare.dk/portal/index.asp?asident=21196>

The proxy form can also be downloaded or printed from the Company's website: <https://www.zealandpharma.com/investors/extraordinary-general-meeting-may-2026> and be sent by post (Computershare A/S, Lottenborgvej 26D, 1st floor, DK-2800 Kgs. Lyngby, Denmark) or e-mail (gf@computershare.dk).

If submitting a proxy form by ordinary mail, please allow sufficient time for postal delivery to ensure that the proxy is received before the deadline.

Postal vote

Shareholders who are unable to attend the General Meeting in person or by proxy can vote by post, i.e. by submitting a vote in writing, prior to the General Meeting. Computershare A/S must have received the postal vote no later than Friday, 22 May 2026 at 11:59 pm (CEST).



It is possible to vote by post electronically directly via the Company's shareholder portal available at <https://portal.computershare.dk/portal/index.asp?asident=21196>

A postal vote form is also available for downloading or printing from the Company's website: <https://www.zealandpharma.com/investors/extraordinary-general-meeting-may-2026>. Once completed, dated and signed, the vote may be sent by post (Computershare A/S, Lottenborgvej 26D, 1st floor, DK-2800 Kgs. Lyngby, Denmark) or by e-mail (gf@computershare.dk).

A postal vote that has been received is irrevocable. In the event that new proposals are submitted, including any amendments to proposals, or in the event of proposals for new candidates to the Board of Directors which are not on the agenda, postal votes will be taken into account if the new proposal is substantially the same as the original proposal.

Processing of personal data

The Privacy Policy for Shareholders etc. explains how the Company processes personal data in connection with the General Meeting. The Policy is available via the shareholder portal in the Investors section of the Company's website: <https://www.zealandpharma.com/privacy-notice/>.

- 0 -

Date: 1 May, 2026

Kind regards,

The Board of Directors of Zealand Pharma A/S



1. Appendix 1

This annex sets out the competencies and current positions of Camilla Sylvest proposed for election to the Board of Directors at the General Meeting.

New candidate

Camilla Sylvest

Board member candidate

Is up for election to the Board at the Extraordinary General Meeting in 2026 and regarded as an independent board member.

Special Competencies

Camilla Sylvest is an experienced global business leader with nearly three decades at Novo Nordisk A/S, where she held senior executive and general management roles across multiple geographies and operating models. Most recently, she served as Executive Vice President for Global Commercial Strategy, Corporate Communication and Sustainability, with responsibility for global commercial strategy, marketing, and major product launches, including drugs in the areas of weight loss management and diabetes.

Throughout her career, Camilla Sylvest has combined strong strategic leadership with hands-on execution, driving large-scale transformations and building high-performing, purpose-driven organizations across the full value chain. She brings significant P&L responsibility from General Manager roles in Novo Nordisk A/S in Region China, Germany, South East Asia & Oceania, Denmark and Norway, as well as deep experience in global corporate and commercial strategy.

Camilla Sylvest holds a Master of Science in Economics and an Executive MBA in strategy and leadership. She has lived and worked in six countries and brings broad board experience from publicly listed companies, foundations, and cooperative structures. Camilla Sylvest also served as a member of the board of directors of Danish Crown A/S from 2017 to 2025.

Current positions

Current board positions include Board Member of argenx SE (since 2022), and Board Member of Getinge AB (since 2026).